The present research work aim was to formulate a sustained release matrix tablet containing Methocarbamol, which is used in the treatment of acute musculoskeletal pain. Sustained release matrix tablet containing methocarbamol was prepared by using the direct compression method. Methocarbamol is having short half life. Sustained release matrix tablet prepared by using Design-Expert version13 software with central composite factorial designs in which drug retardant polymer HPMC K100M and binder like xanthan gum are used in different concentrations. The formulated batches of tablets were evaluated for hardness test, weight variation test, friability test, drug content, and in vitro % drug release. The characterization of the tablet shows satisfactory results of a tablet like weight variation and thickness. The formulation F4 showed the highest amount of drug content. FTIR and DSC studies reveal that there are no interactions between drug and excipients that mean drugs and excipients are compatible with each other. Formulation F4 is optimized batch, passes evaluation parameters and maximum % drug release i.e. 100.14 % upto12 hrs. Therefore, the sustained release matrix tablet is an effective approach for avoiding daily multiple doses and for better patient compliance.